Drugs of Abuse Testing Assays

6-Acetylmorphine

AB-PINACA

Amphetamines

  • Immunalysis Amphetamines HEIA

Barbiturates

  • Immunalysis Barbiturates HEIA

Benzodiazepines

Benzoylecgonine (Cocaine Metab.)

  • Immunalysis Benzoylecgonine HEIA

Buprenorphine

Cannabinoids

  • Immunalysis Cannabinoids HEIA

Carisoprodol

  • Immunalysis Carisoprodol HEIA

EDDP

Ethylglucuronide (EtG)

Fentanyl

JWH-018

Ketamine

Meperidine

  • ARK Meperidine Assay
  • Immunalysis Meperidine HEIA

Methamphetamine

  • Immunalysis Methamphetamine HEIA

Methylphenidate-Metabolite

Opiates

  • Immunalysis Opiates HEIA

Oxycodone

  • Immunalysis Oxycodone HEIA

Phencyclidine (PCP)

  • Immunalysis Phencyclidine HEIA

Pregabalin

Tapentadol

  • Immunalysis Tapentadol HEIA

Tramadol

  • ARK Diagnostics Tramadol Assay
  • Immunalysis Tramadol HEIA

UR-144 / XLR-11

Zolpidem

  • Immunalysis Zolpidem HEIA

ARK Pregabalin II Assay

The ARK Pregabalin II Assay provides a reliable and fast method for detecting pregabalin in urine. This innovative homogeneous enzyme immunoassay serves as a straightforward alternative to more complex chromatographic methods, making it particularly useful for monitoring potential cases of pregabalin abuse. Its compatibility with major clinical-chemistry systems allows for easy integration into current drug screening processes.

Assay Characteristics
  • Rapid and convenient screening method
  • Highly specific method for the determination of pregabalin in human urine
  • No cross-reactivity with gabapentin at 5,000 µg/mL
  • No cross-reactivity with L-amino acids at 200 µg/mL
  • Tested endogenous compounds did not show any interference with the assay
  • Liquid, ready-to-use reagents, calibrators and controls
  • Storage at 2-8°C
  • On-board stability for at least 60 days
  • Application protocols for all major clinical chemistry analyzers
Background
Pregabalin is an anticonvulsant that was developed as a successor to gabapentin, to which it is structurally closely related. It is the drug of choice for central and peripheral neuropathic disorders and is also used in the treatment of fibromyalgia and certain forms of epilepsy.
Pregabalin is 92-99% excreted unchanged in the urine, with a half-life of around 6 to 7 hours. Despite an officially low potential for abuse, there are increasing publications on actual abuse, especially in patients with previous addictions. Regular use can lead to tolerance and dependence, accompanied by severe withdrawal symptoms.
Side effects include euphoria, relaxation, a significant increase in self-esteem, loss of inhibitions, concentration disorders, dizziness, and visual disturbances. In combination with alcohol, benzodiazepines, or opioids, these effects can be potentiated.
PDF

Do you have any questions for us?